Medical Care
Global Long-Acting Cholesterol-Lowering Drugs Market Research Report 2025
- Mar 27, 25
- ID: 159175
- Pages: 73
- Figures: 75
- Views: 41
The global market for Long-Acting Cholesterol-Lowering Drugs was valued at US$ 1674 million in the year 2024 and is projected to reach a revised size of US$ 2316 million by 2031, growing at a CAGR of 5.5% during the forecast period.
Long-acting cholesterol-lowering drugs are a class of medications that can continuously reduce cholesterol levels in the blood. These drugs typically inhibit the synthesis or absorption of cholesterol, reducing its accumulation in the body. The hallmark of long-acting cholesterol-lowering drugs is their long half-life and sustained efficacy, allowing patients to maintain stable cholesterol levels with fewer doses. These drugs play a crucial role in treating hypercholesterolemia and preventing cardiovascular diseases. Common long-acting cholesterol-lowering drugs include statins and certain novel agents, such as pcsk9 inhibitors. By continuously lowering cholesterol levels, these drugs help reduce the risk of cardiovascular diseases and improve patients' quality.
North American market for Long-Acting Cholesterol-Lowering Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-Acting Cholesterol-Lowering Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Long-Acting Cholesterol-Lowering Drugs in Hyperlipidemia is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long-Acting Cholesterol-Lowering Drugs include LEQVIO (Novartis), Verve Therapeutics, Jiangsu Hengrui Pharmaceuticals, Amgen, Sanofi, Innovent, Akesobio, Junshi Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Cholesterol-Lowering Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Cholesterol-Lowering Drugs.
The Long-Acting Cholesterol-Lowering Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-Acting Cholesterol-Lowering Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Cholesterol-Lowering Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
LEQVIO (Novartis)
Verve Therapeutics
Jiangsu Hengrui Pharmaceuticals
Amgen
Sanofi
Innovent
Akesobio
Junshi Biosciences
Segment by Type
Long-Acting Cholesterol-Lowering Drugs
Ultra-Long-Acting Cholesterol-Lowering Drugs
Segment by Application
Hyperlipidemia
Hypertension
Diabetes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Cholesterol-Lowering Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Long-acting cholesterol-lowering drugs are a class of medications that can continuously reduce cholesterol levels in the blood. These drugs typically inhibit the synthesis or absorption of cholesterol, reducing its accumulation in the body. The hallmark of long-acting cholesterol-lowering drugs is their long half-life and sustained efficacy, allowing patients to maintain stable cholesterol levels with fewer doses. These drugs play a crucial role in treating hypercholesterolemia and preventing cardiovascular diseases. Common long-acting cholesterol-lowering drugs include statins and certain novel agents, such as pcsk9 inhibitors. By continuously lowering cholesterol levels, these drugs help reduce the risk of cardiovascular diseases and improve patients' quality.
North American market for Long-Acting Cholesterol-Lowering Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-Acting Cholesterol-Lowering Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Long-Acting Cholesterol-Lowering Drugs in Hyperlipidemia is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long-Acting Cholesterol-Lowering Drugs include LEQVIO (Novartis), Verve Therapeutics, Jiangsu Hengrui Pharmaceuticals, Amgen, Sanofi, Innovent, Akesobio, Junshi Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Cholesterol-Lowering Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Cholesterol-Lowering Drugs.
The Long-Acting Cholesterol-Lowering Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-Acting Cholesterol-Lowering Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Cholesterol-Lowering Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
LEQVIO (Novartis)
Verve Therapeutics
Jiangsu Hengrui Pharmaceuticals
Amgen
Sanofi
Innovent
Akesobio
Junshi Biosciences
Segment by Type
Long-Acting Cholesterol-Lowering Drugs
Ultra-Long-Acting Cholesterol-Lowering Drugs
Segment by Application
Hyperlipidemia
Hypertension
Diabetes
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Cholesterol-Lowering Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Long-Acting Cholesterol-Lowering Drugs
1.2.3 Ultra-Long-Acting Cholesterol-Lowering Drugs
1.3 Market by Application
1.3.1 Global Long-Acting Cholesterol-Lowering Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hyperlipidemia
1.3.3 Hypertension
1.3.4 Diabetes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Cholesterol-Lowering Drugs Market Perspective (2020-2031)
2.2 Global Long-Acting Cholesterol-Lowering Drugs Growth Trends by Region
2.2.1 Global Long-Acting Cholesterol-Lowering Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Long-Acting Cholesterol-Lowering Drugs Historic Market Size by Region (2020-2025)
2.2.3 Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Region (2026-2031)
2.3 Long-Acting Cholesterol-Lowering Drugs Market Dynamics
2.3.1 Long-Acting Cholesterol-Lowering Drugs Industry Trends
2.3.2 Long-Acting Cholesterol-Lowering Drugs Market Drivers
2.3.3 Long-Acting Cholesterol-Lowering Drugs Market Challenges
2.3.4 Long-Acting Cholesterol-Lowering Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Cholesterol-Lowering Drugs Players by Revenue
3.1.1 Global Top Long-Acting Cholesterol-Lowering Drugs Players by Revenue (2020-2025)
3.1.2 Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top Long-Acting Cholesterol-Lowering Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Long-Acting Cholesterol-Lowering Drugs Revenue
3.4 Global Long-Acting Cholesterol-Lowering Drugs Market Concentration Ratio
3.4.1 Global Long-Acting Cholesterol-Lowering Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Cholesterol-Lowering Drugs Revenue in 2024
3.5 Global Key Players of Long-Acting Cholesterol-Lowering Drugs Head office and Area Served
3.6 Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Product and Application
3.7 Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Cholesterol-Lowering Drugs Breakdown Data by Type
4.1 Global Long-Acting Cholesterol-Lowering Drugs Historic Market Size by Type (2020-2025)
4.2 Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Type (2026-2031)
5 Long-Acting Cholesterol-Lowering Drugs Breakdown Data by Application
5.1 Global Long-Acting Cholesterol-Lowering Drugs Historic Market Size by Application (2020-2025)
5.2 Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
6.2 North America Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
6.4 North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
7.2 Europe Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
7.4 Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
8.2 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
9.2 Latin America Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
9.4 Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
10.2 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 LEQVIO (Novartis)
11.1.1 LEQVIO (Novartis) Company Details
11.1.2 LEQVIO (Novartis) Business Overview
11.1.3 LEQVIO (Novartis) Long-Acting Cholesterol-Lowering Drugs Introduction
11.1.4 LEQVIO (Novartis) Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.1.5 LEQVIO (Novartis) Recent Development
11.2 Verve Therapeutics
11.2.1 Verve Therapeutics Company Details
11.2.2 Verve Therapeutics Business Overview
11.2.3 Verve Therapeutics Long-Acting Cholesterol-Lowering Drugs Introduction
11.2.4 Verve Therapeutics Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.2.5 Verve Therapeutics Recent Development
11.3 Jiangsu Hengrui Pharmaceuticals
11.3.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.3.3 Jiangsu Hengrui Pharmaceuticals Long-Acting Cholesterol-Lowering Drugs Introduction
11.3.4 Jiangsu Hengrui Pharmaceuticals Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.3.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Long-Acting Cholesterol-Lowering Drugs Introduction
11.4.4 Amgen Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.4.5 Amgen Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Long-Acting Cholesterol-Lowering Drugs Introduction
11.5.4 Sanofi Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.5.5 Sanofi Recent Development
11.6 Innovent
11.6.1 Innovent Company Details
11.6.2 Innovent Business Overview
11.6.3 Innovent Long-Acting Cholesterol-Lowering Drugs Introduction
11.6.4 Innovent Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.6.5 Innovent Recent Development
11.7 Akesobio
11.7.1 Akesobio Company Details
11.7.2 Akesobio Business Overview
11.7.3 Akesobio Long-Acting Cholesterol-Lowering Drugs Introduction
11.7.4 Akesobio Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.7.5 Akesobio Recent Development
11.8 Junshi Biosciences
11.8.1 Junshi Biosciences Company Details
11.8.2 Junshi Biosciences Business Overview
11.8.3 Junshi Biosciences Long-Acting Cholesterol-Lowering Drugs Introduction
11.8.4 Junshi Biosciences Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.8.5 Junshi Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Long-Acting Cholesterol-Lowering Drugs
1.2.3 Ultra-Long-Acting Cholesterol-Lowering Drugs
1.3 Market by Application
1.3.1 Global Long-Acting Cholesterol-Lowering Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hyperlipidemia
1.3.3 Hypertension
1.3.4 Diabetes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Cholesterol-Lowering Drugs Market Perspective (2020-2031)
2.2 Global Long-Acting Cholesterol-Lowering Drugs Growth Trends by Region
2.2.1 Global Long-Acting Cholesterol-Lowering Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Long-Acting Cholesterol-Lowering Drugs Historic Market Size by Region (2020-2025)
2.2.3 Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Region (2026-2031)
2.3 Long-Acting Cholesterol-Lowering Drugs Market Dynamics
2.3.1 Long-Acting Cholesterol-Lowering Drugs Industry Trends
2.3.2 Long-Acting Cholesterol-Lowering Drugs Market Drivers
2.3.3 Long-Acting Cholesterol-Lowering Drugs Market Challenges
2.3.4 Long-Acting Cholesterol-Lowering Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Cholesterol-Lowering Drugs Players by Revenue
3.1.1 Global Top Long-Acting Cholesterol-Lowering Drugs Players by Revenue (2020-2025)
3.1.2 Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top Long-Acting Cholesterol-Lowering Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Long-Acting Cholesterol-Lowering Drugs Revenue
3.4 Global Long-Acting Cholesterol-Lowering Drugs Market Concentration Ratio
3.4.1 Global Long-Acting Cholesterol-Lowering Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Cholesterol-Lowering Drugs Revenue in 2024
3.5 Global Key Players of Long-Acting Cholesterol-Lowering Drugs Head office and Area Served
3.6 Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Product and Application
3.7 Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Cholesterol-Lowering Drugs Breakdown Data by Type
4.1 Global Long-Acting Cholesterol-Lowering Drugs Historic Market Size by Type (2020-2025)
4.2 Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Type (2026-2031)
5 Long-Acting Cholesterol-Lowering Drugs Breakdown Data by Application
5.1 Global Long-Acting Cholesterol-Lowering Drugs Historic Market Size by Application (2020-2025)
5.2 Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
6.2 North America Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
6.4 North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
7.2 Europe Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
7.4 Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
8.2 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
9.2 Latin America Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
9.4 Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size (2020-2031)
10.2 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 LEQVIO (Novartis)
11.1.1 LEQVIO (Novartis) Company Details
11.1.2 LEQVIO (Novartis) Business Overview
11.1.3 LEQVIO (Novartis) Long-Acting Cholesterol-Lowering Drugs Introduction
11.1.4 LEQVIO (Novartis) Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.1.5 LEQVIO (Novartis) Recent Development
11.2 Verve Therapeutics
11.2.1 Verve Therapeutics Company Details
11.2.2 Verve Therapeutics Business Overview
11.2.3 Verve Therapeutics Long-Acting Cholesterol-Lowering Drugs Introduction
11.2.4 Verve Therapeutics Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.2.5 Verve Therapeutics Recent Development
11.3 Jiangsu Hengrui Pharmaceuticals
11.3.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.3.3 Jiangsu Hengrui Pharmaceuticals Long-Acting Cholesterol-Lowering Drugs Introduction
11.3.4 Jiangsu Hengrui Pharmaceuticals Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.3.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Long-Acting Cholesterol-Lowering Drugs Introduction
11.4.4 Amgen Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.4.5 Amgen Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Long-Acting Cholesterol-Lowering Drugs Introduction
11.5.4 Sanofi Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.5.5 Sanofi Recent Development
11.6 Innovent
11.6.1 Innovent Company Details
11.6.2 Innovent Business Overview
11.6.3 Innovent Long-Acting Cholesterol-Lowering Drugs Introduction
11.6.4 Innovent Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.6.5 Innovent Recent Development
11.7 Akesobio
11.7.1 Akesobio Company Details
11.7.2 Akesobio Business Overview
11.7.3 Akesobio Long-Acting Cholesterol-Lowering Drugs Introduction
11.7.4 Akesobio Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.7.5 Akesobio Recent Development
11.8 Junshi Biosciences
11.8.1 Junshi Biosciences Company Details
11.8.2 Junshi Biosciences Business Overview
11.8.3 Junshi Biosciences Long-Acting Cholesterol-Lowering Drugs Introduction
11.8.4 Junshi Biosciences Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
11.8.5 Junshi Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Long-Acting Cholesterol-Lowering Drugs
Table 3. Key Players of Ultra-Long-Acting Cholesterol-Lowering Drugs
Table 4. Global Long-Acting Cholesterol-Lowering Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Region (2020-2025)
Table 8. Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Region (2026-2031)
Table 10. Long-Acting Cholesterol-Lowering Drugs Market Trends
Table 11. Long-Acting Cholesterol-Lowering Drugs Market Drivers
Table 12. Long-Acting Cholesterol-Lowering Drugs Market Challenges
Table 13. Long-Acting Cholesterol-Lowering Drugs Market Restraints
Table 14. Global Long-Acting Cholesterol-Lowering Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Players (2020-2025)
Table 16. Global Top Long-Acting Cholesterol-Lowering Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Cholesterol-Lowering Drugs as of 2024)
Table 17. Ranking of Global Top Long-Acting Cholesterol-Lowering Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Long-Acting Cholesterol-Lowering Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Headquarters and Area Served
Table 20. Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Product and Application
Table 21. Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. LEQVIO (Novartis) Company Details
Table 47. LEQVIO (Novartis) Business Overview
Table 48. LEQVIO (Novartis) Long-Acting Cholesterol-Lowering Drugs Product
Table 49. LEQVIO (Novartis) Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 50. LEQVIO (Novartis) Recent Development
Table 51. Verve Therapeutics Company Details
Table 52. Verve Therapeutics Business Overview
Table 53. Verve Therapeutics Long-Acting Cholesterol-Lowering Drugs Product
Table 54. Verve Therapeutics Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 55. Verve Therapeutics Recent Development
Table 56. Jiangsu Hengrui Pharmaceuticals Company Details
Table 57. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 58. Jiangsu Hengrui Pharmaceuticals Long-Acting Cholesterol-Lowering Drugs Product
Table 59. Jiangsu Hengrui Pharmaceuticals Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 60. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 61. Amgen Company Details
Table 62. Amgen Business Overview
Table 63. Amgen Long-Acting Cholesterol-Lowering Drugs Product
Table 64. Amgen Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 65. Amgen Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Long-Acting Cholesterol-Lowering Drugs Product
Table 69. Sanofi Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Innovent Company Details
Table 72. Innovent Business Overview
Table 73. Innovent Long-Acting Cholesterol-Lowering Drugs Product
Table 74. Innovent Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 75. Innovent Recent Development
Table 76. Akesobio Company Details
Table 77. Akesobio Business Overview
Table 78. Akesobio Long-Acting Cholesterol-Lowering Drugs Product
Table 79. Akesobio Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 80. Akesobio Recent Development
Table 81. Junshi Biosciences Company Details
Table 82. Junshi Biosciences Business Overview
Table 83. Junshi Biosciences Long-Acting Cholesterol-Lowering Drugs Product
Table 84. Junshi Biosciences Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 85. Junshi Biosciences Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
Table 89. Authors List of This Report
List of Figures
Figure 1. Long-Acting Cholesterol-Lowering Drugs Picture
Figure 2. Global Long-Acting Cholesterol-Lowering Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Type: 2024 VS 2031
Figure 4. Long-Acting Cholesterol-Lowering Drugs Features
Figure 5. Ultra-Long-Acting Cholesterol-Lowering Drugs Features
Figure 6. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hyperlipidemia Case Studies
Figure 9. Hypertension Case Studies
Figure 10. Diabetes Case Studies
Figure 11. Others Case Studies
Figure 12. Long-Acting Cholesterol-Lowering Drugs Report Years Considered
Figure 13. Global Long-Acting Cholesterol-Lowering Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Long-Acting Cholesterol-Lowering Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Region: 2024 VS 2031
Figure 16. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Players in 2024
Figure 17. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Long-Acting Cholesterol-Lowering Drugs Revenue in 2024
Figure 19. North America Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 21. United States Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 25. Germany Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Share by Region (2020-2031)
Figure 33. China Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 41. Mexico Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 45. Turkey Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. LEQVIO (Novartis) Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 49. Verve Therapeutics Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 50. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 51. Amgen Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 52. Sanofi Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 53. Innovent Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 54. Akesobio Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 55. Junshi Biosciences Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Table 1. Global Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Long-Acting Cholesterol-Lowering Drugs
Table 3. Key Players of Ultra-Long-Acting Cholesterol-Lowering Drugs
Table 4. Global Long-Acting Cholesterol-Lowering Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Region (2020-2025)
Table 8. Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Region (2026-2031)
Table 10. Long-Acting Cholesterol-Lowering Drugs Market Trends
Table 11. Long-Acting Cholesterol-Lowering Drugs Market Drivers
Table 12. Long-Acting Cholesterol-Lowering Drugs Market Challenges
Table 13. Long-Acting Cholesterol-Lowering Drugs Market Restraints
Table 14. Global Long-Acting Cholesterol-Lowering Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Players (2020-2025)
Table 16. Global Top Long-Acting Cholesterol-Lowering Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Cholesterol-Lowering Drugs as of 2024)
Table 17. Ranking of Global Top Long-Acting Cholesterol-Lowering Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Long-Acting Cholesterol-Lowering Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Headquarters and Area Served
Table 20. Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Product and Application
Table 21. Global Key Players of Long-Acting Cholesterol-Lowering Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Long-Acting Cholesterol-Lowering Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Long-Acting Cholesterol-Lowering Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. LEQVIO (Novartis) Company Details
Table 47. LEQVIO (Novartis) Business Overview
Table 48. LEQVIO (Novartis) Long-Acting Cholesterol-Lowering Drugs Product
Table 49. LEQVIO (Novartis) Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 50. LEQVIO (Novartis) Recent Development
Table 51. Verve Therapeutics Company Details
Table 52. Verve Therapeutics Business Overview
Table 53. Verve Therapeutics Long-Acting Cholesterol-Lowering Drugs Product
Table 54. Verve Therapeutics Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 55. Verve Therapeutics Recent Development
Table 56. Jiangsu Hengrui Pharmaceuticals Company Details
Table 57. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 58. Jiangsu Hengrui Pharmaceuticals Long-Acting Cholesterol-Lowering Drugs Product
Table 59. Jiangsu Hengrui Pharmaceuticals Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 60. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 61. Amgen Company Details
Table 62. Amgen Business Overview
Table 63. Amgen Long-Acting Cholesterol-Lowering Drugs Product
Table 64. Amgen Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 65. Amgen Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Long-Acting Cholesterol-Lowering Drugs Product
Table 69. Sanofi Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Innovent Company Details
Table 72. Innovent Business Overview
Table 73. Innovent Long-Acting Cholesterol-Lowering Drugs Product
Table 74. Innovent Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 75. Innovent Recent Development
Table 76. Akesobio Company Details
Table 77. Akesobio Business Overview
Table 78. Akesobio Long-Acting Cholesterol-Lowering Drugs Product
Table 79. Akesobio Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 80. Akesobio Recent Development
Table 81. Junshi Biosciences Company Details
Table 82. Junshi Biosciences Business Overview
Table 83. Junshi Biosciences Long-Acting Cholesterol-Lowering Drugs Product
Table 84. Junshi Biosciences Revenue in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025) & (US$ Million)
Table 85. Junshi Biosciences Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
Table 89. Authors List of This Report
List of Figures
Figure 1. Long-Acting Cholesterol-Lowering Drugs Picture
Figure 2. Global Long-Acting Cholesterol-Lowering Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Type: 2024 VS 2031
Figure 4. Long-Acting Cholesterol-Lowering Drugs Features
Figure 5. Ultra-Long-Acting Cholesterol-Lowering Drugs Features
Figure 6. Global Long-Acting Cholesterol-Lowering Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hyperlipidemia Case Studies
Figure 9. Hypertension Case Studies
Figure 10. Diabetes Case Studies
Figure 11. Others Case Studies
Figure 12. Long-Acting Cholesterol-Lowering Drugs Report Years Considered
Figure 13. Global Long-Acting Cholesterol-Lowering Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Long-Acting Cholesterol-Lowering Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Region: 2024 VS 2031
Figure 16. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Players in 2024
Figure 17. Global Long-Acting Cholesterol-Lowering Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Long-Acting Cholesterol-Lowering Drugs Revenue in 2024
Figure 19. North America Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 21. United States Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 25. Germany Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Long-Acting Cholesterol-Lowering Drugs Market Share by Region (2020-2031)
Figure 33. China Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 41. Mexico Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Long-Acting Cholesterol-Lowering Drugs Market Share by Country (2020-2031)
Figure 45. Turkey Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Long-Acting Cholesterol-Lowering Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. LEQVIO (Novartis) Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 49. Verve Therapeutics Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 50. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 51. Amgen Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 52. Sanofi Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 53. Innovent Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 54. Akesobio Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 55. Junshi Biosciences Revenue Growth Rate in Long-Acting Cholesterol-Lowering Drugs Business (2020-2025)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232